Nurix Therapeutics shares rise 3.38% after-hours following positive sector updates and strategic partnerships.

Nurix Therapeutics, Inc. rose 3.38% in after-hours trading. The company's stock price increase may be attributed to the positive outlook from UBS, which reiterated its Buy rating for the stock with a target price of EUR 115. Additionally, the news about John C. Martin, who is on the board of Sarepta Therapeutics, Inc. and has a significant background in the healthcare industry, may have contributed to the positive sentiment surrounding the stock.